From: Piperacillin–tazobactam as alternative to carbapenems for ICU patients
Author/year of publication | Study design, region | No. of patients, ESBL/total | Type of infection (n, %) | Bacteria (n, %) | ICU (n, %) | ETC/DTC | Treatment (n, %) | MIC | Administration (CI, PI or II) | Posology |
---|---|---|---|---|---|---|---|---|---|---|
Apisarnthanarak et al. [52] | SC case–control, 2003–2007, Thailand | 36/146 | UK (36, 100%) | E. coli K. pneumoniae | UK | ETC (36, 100%) | Cephalosporins (17, 47.2%) BL/BLI (10, 27.8%) Carbapenem (5, 13.9%) Fluoroquinolones (4, 11.1%) | N | UK | UK |
Balakrishnan et al. [94] | MC retrospective cohort, 2008–2010, United Kingdom | 42/42 | UK | UK | UK | DTC (42, 100%) | Temocillin (42, 100%) | Y | II | Y |
Bin et al. [95] | SC prospective cohort, 2002–2005, China | 22/22 | IIA (11, 50%) Primary bacteraemia (6, 27.2%) UTI (5, 22.7%) | E. coli (22, 100%) | UK | DTC (22, 100%) | Carbapenem (8, 36.4%) Cephalosporins (7, 31.8%) BL/BLI (7, 31.8%) | Y | Y | UK |
Chaubey et al. [96] | MC prospective cohort, 2000–2007, Canada | 79/79 | Primary bacteraemia (39, 49.3%) UTI (38, 48.1%) Pneumonia (2, 2.5%) IIA (1, 1.3%) | E. coli (72, 91.1%) K. pneumoniae (7, 8.9%) | UK | ETC (74, 93.7%) DTC (79, 100%) | Carbapenem (16, 20.2%) BL/BLI (16, 20.2%) Aminoglycosides (16, 20.2%) Fluoroquinolones (16, 20.2%) Cephalosporins (16, 20.2%) Carbapenem (16, 20.2%) BL/BLI (16, 20.2%) Fluoroquinolones (16, 20.2%) Sulfamides (16, 20.2%) Aminoglycosides (16, 20.2%) | N | UK | UK |
Chopra et al. [50] | MC retrospective cohort, 2005–2007, USA | 145/145 | UK | E. coli (24, 16.6%) K. pneumoniae (121, 83.4%) | Y (37, 25,5%) | ETC (128, 88.2%) DTC (110) | Cephalosporins (85, 58.6%) Carbapenem (50, 34.4%) Fluoroquinolones (6, 3.9%) Aminoglycosides (4, 3.1%) Carbapenem (103, 70.9%) Cephalosporins (41, 28.2%) BL/BLI (24, 16.4%) Fluoroquinolones (17, 11.8%) Amikacin (17, 11.8%) Tigecycline (12, 8.2%) | Y | UK | UK |
Chung et al. [97] | SC retrospective cohort, 2005–2010, Taiwan | 122/122 | UTI (47, 38.5%) Primary bacteraemia (21, 17.2%) IIA (22, 18%) Pneumonia (6, 4.9%) CVC (6, 4.9%) Skin and soft tissue (4, 3.3%) Surgical site infection (3, 2.5%) Other (13, 10.7%) | E. coli (122, 100%) | UK | DTC (107 87.7%) | Carbapenem (71, 57.9%) Non-BL/BLI (48, 39.3%) BL/BLI (3, 2.8%) | N | UK | UK |
De Rosa et al. [98] | SC retrospective cohort, 2000–2007, Italy | 128/128 | Primary bacteraemia (61, 47.6%) IIA (55, 43%) UTI (12, 9.4%) | E. coli (80, 62.5%) K. pneumoniae (28, 21.9%) P. mirabilis (20, 15.6%) | Y (8, 6.3%) | ETC (97 75.8%) | Carbapenem (101, 79.3%) BL/BLI (10, 8.2%) Fluoroquinolone (8, 6.2%) Trimethoprim/sulfamethoxazole (1, 1%) Aminoglycosides (8, 6.2%) | N | UK | UK |
Du et al. [16] | SC retrospective cohort, 1997–1999, China | 23/85 | Primary bacteraemia (9, 39.1%) IIA (5, 21.7%) Pneumonia (4, 17.4%) UTI (2, 8.7%) CVC (2, 8.7%) Other (1, 4.4%) | E. coli (16, 69.5%) K. pneumoniae (7, 30.5%) | N | DTC (23, 100%) | Carbapenem (13, 56.5%) Cephalosporins (7, 30.4%) Fluoroquinolone (2, 8.7%) Aminoglycosides (1, 4.4%) | N | UK | UK |
Endimiani et al. [99] | SC retrospective cohort, 1997–2004, Italy | 9/23 | Primary bacteraemia (5, 55.6%) UTI (4, 44.4%) | P. mirabilis (9, 100%) | UK | ETC (9, 100%) DTC (9, 100%) | Cephalosporins (5, 55.6%) BL/BLI (4, 44.4%) Cephalosporins (4, 44.4%) BL/BLI (3, 33.3%) Carbapenem (2, 22.3%) | Y | Y | UK |
Ferrandez et al. [100] | Retrospective cohort, 2000–2006, Spain | 53/53 | UK | E. coli K. pneumoniae | UK | – | Carbapenem (30, 56.6%) BL/BLI (5, 9.4%) Fluoroquinolone (4, 7.5%) Cephalosporins (2, 3.8%) Other (12, 22.7%) | Y | UK | UK |
Gudiol et al. [101] | SC prospective observational study, 2006–2008, Spain | 17/135 | Primary bacteraemia (9, 52.9%) IIA (6, 35.3%) UTI (1, 5.9%) Other (1, 5.9%) | E. coli (17, 100%) | Y (2, 12%) | ETC (17, 100%) DTC (17, 100%) | BL/BLI (6, 35.3%) Carbapenem (5, 29.4%) Cephalosporins (5, 29.4%) Monobactam (1, 5.9%) Carbapenem (14, 82.3%) BL/BLI (2, 11.8%) Fluoroquinolone (1, 5.9%) | N | UK | UK |
Gutiérez-Gutiérez et al. [51] | MC, retrospective cohort study, 2004–2013, International | 601/601 | UTI (272, 45.2%) Other (258, 42.9%) IIA (71, 11.8%) | E. coli (439, 73%) K. pneumoniae (114, 19%) Other (48, 8%) | Y (64, 10.7%) | ETC (365, 60.7%) DTC (601, 100%) | Carbapenem (195, 53.5%) BL/BLI (169, 46.5%) Carbapenem (509, 84.7%) BL/BLI (92, 15.3%) | N | Y | II |
Harris et al. [102] | SC retrospective cohort study, 2012–2013, China | 92/92 | UTI (43, 46.7%) Primary bacteramia (39, 42.2%) IIA (10, 11.1%) | E. coli (79, 85.9%) K. pneumoniae (13, 14.1%) | Y (11, 12.1%) | DTC (47, 51%) | Carbapenem (23, 48.9%) BL/BLI (24, 51.1%) | N | Y | II |
Kang et al. [17] | SC retrospective cohort study, 1998–2002, South Korea | 133/133 | IIA (82, 61.6%) Primary bacteraemia (33, 24.8%) UTI (14, 10.5%) Pneumonia (4, 3.1%) | E. coli (67, 50.4%) K. pneumoniae (66, 49.6%) | N | ETC (133, 100%) DTC (133, 100%) | Non cephalosporins (29, 21.8%) Cephalosporins (104, 78.2%) Non cephalosporins (101, 75.9%) Cephalosporins (32, 24.1%) | Y | UK | UK |
Kang et al. [69] | MC retrospective cohorts, 2008–2010, South Korea | 114/114 | UK | E. coli (78, 68.4%) K. pneumonia (36, 31.6%) | UK | ETC (114 100%) | Carbapenem (78, 68.4%) Piperacillin/tazobactam (36, 31.6%) | N | UK | UK |
Lee et al. [53] | SC retrospective cohort, 2004–2005, Taiwan | 27/27 | Pneumonia (15, 55.5%) IIA (5, 18.5%) UTI (3, 11.1%) Primary bacteraemia (3, 11.1%) Other (1, 3.8%) | K. pneumonia (27, 100%) | Y (13, 48.1%) | DTC (27, 100%) | Carbapenem (20, 74%) Flomoxef (7, 26%) | Y | UK | UK |
Lee and al. [21] | SC retrospective cohort, 2001–2008, Taiwan | 121/206 | CVC (48, 39.6%) Primary bacteraemia (32, 26.4%) Pneumonia (12, 9.9%) SSTI (9, 7.4%) UTI (9, 7.4%) IIA (6, 4.9%) Other (5, 4.3%) | E. cloacae (121, 100%) | Y (78, 64.4%) | ETC (114, 94.2%) DTC (114, 94.2%) | Cephalosporins (59, 49.1%) Carbapenem (26, 21%) BL/BLI (14, 11.4%) Other beta-lactam (13, 10.5%) Fluoroquinolones (3, 2.6%) Other Antibiotics (6, 5.4%) Carbapenem (53, 46.5%) Cephalosporins (38, 33.3%) Fluoroquinolones (16, 14%) BL/BLI (3, 2.6%) Other β-lactam (3, 2.6%) Other antibiotic therapy (1, 1%) | N | UK | UK |
Lee et al. [54] | MC retrospective cohort, 2002–2007, Taiwan | 178/178 | Pneumonia (43, 24.1%) UTI (39, 21.9%) CVC (37, 20.8%) IIA (28, 15.7%) Primary bacteraemia (25, 14%) SSTI (11, 6.3%) | ND | UK | DTC (178, 100%) | Carbapenem (161, 90,4%) Cefepime (17, 9.6%) | Y | Y | II |
Lee et al. [103] | MC retrospective cohort, 2007–2012, Taiwan | 389/389 | UTI (88, 22.6%) CVC (86, 22.1%) Pneumonia (80, 20.5%) IIA (61, 15.7%) Primary bacteraemia (62, 16%) SSTI (12, 3.1%) | E. coli (156, 40.1%) K. pneumoniae (233, 59.9%) | UK | DTC (389, 100%) | Carbapenem (257, 66%) Flomoxef (132, 34%) | Y | UK | UK |
Matsumura et al. [104] | MC retrospective cohort, 2005–2014, Japan | 113/1440 | UTI (57, 50.4%) IIA (32, 28.3%) Primary bacteraemia (19, 16.8%) Other (5, 4.5%) | E. coli (113, 100%) | UK | ETC (71, 62.8%) DTC (113, 100%) | Carbapenem (45, 63.7%) Cefmetazole/flomoxef (26, 36.6%) Carbapenem (54, 47.8%) Cefmetazole/flomoxef (59, 52.2%) | Y | UK | UK |
Ofer-Friedman et al. [20] | MC retrospective cohort, 2008–2012, International | 79/79 | Pneumonia (27, 34.2%) SSTI (22, 27.8%) IIA (20, 25.3%) Primary bacteraemia (6, 7.6%) Undetermined (4, 5.1%) | E. coli (42, 53.1%) K. pneumoniae (22, 27.8%) P. mirabilis (15, 19.1%) | > 50% | ETC (33, 41.8%) DTC (79, 100%) | Carbapenem (24, 72.7%) Piperacillin/tazobactam (9, 27.3%) Carbapenem (69, 87.3%) Piperacillin/tazobactam (10, 12.7%) | Y | UK | UK |
Qureshi et al. [105] | MC retrospective cohort, 2005–2008, USA | 21/UK | UK | E. cloacae (21, 100%) | UK | ETC (21, 100%) | Cephalosporins (9, 42.8%) Carbapenem (8, 38%) BL/BLI (4, 19.2%) | Y | UK | UK |
Paterson et al. [55] | Post hoc analysis MC prospective cohort, 1996–1997, International | 85/455 | UK | K. pneumoniae (85, 100%) | UK | ETC (71, 83.5%) | Monotherapy Carbapenem (27, 38%) Fluoroquinolones (11, 15.5%) Cephalosporins (5, 7%) BL/BLI (4, 5.6%) Aminoglycosides (2, 2.8%) Combination therapy (15, 21.1%) Sequential monotherapy (7, 10%) | N | UK | UK |
Pilmis et al. [106] | MC retrospective cohort, 2011, France | 13/13 | Primary bacteraemia (11, 84.6%) UTI (2, 15.4%) | E. coli (5, 38.4%) K. pneumoniae (7, 53.8%) E. cloacae (1, 7.8%) | UK | ETC (13, 100%) DTC (13, 100%) | Carbapenem (12, 92.3%) Cefoxitin (1, 7.7%) Carbapenem (11, 84.6%) Cefoxitin (2, 15.4%) | N | UK | UK |
Retamar et al. [107] | Post hoc analysis MC prospective cohort, 2001–2007, Spain | 39/39 | UTI (11, 28.2%) Other source (28, 71.8%) | E. coli (39, 100%) | UK | ETC (39, 100%) | BL/BLI (39, 100%) | Y | UK | UK |
Rodriguez-Bano et al. [12] | Post hoc analysis MC prospective cohorts, 2001–2007, Spain | 192/192 | UTI or IIA (121, 63%) Other sources (71, 37%) | E. coli (192, 100%) | Y (24, 12.6%) | ETC (103, 53.6%) DTC (174, 90.6%) | Carbapenem (31, 30%) BL/BLI (72, 70%) Carbapenem (120, 68.9%) BL/BLI (53, 31.1%) | N | UK | UK |
Tamma et al. [19] | MC, Prospective cohort, 2008–2015, USA | 213/331 | CVC (97, 45.5%) IIA (55, 25.8%) UTI (44, 20.6%) Pneumonia (17, 8.1%) | K. pneumoniae (145, 68%) E. coli (66, 31%) P. mirabilis (2, 1%) | Y (71, 33.3%) | ETC (213, 100%) | Carbapenem (110, 51.6%) BL/BLI (103, 48.4%) | Y | UK | UK |
Tsai et al. [108] | MC retrospective cohort, 2005–2012, Taiwan | 47/47 | UTI (24, 51%) Pneumonia (9, 19.1%) SSTI (7, 14.9%) CVC (5, 10.6%) IIA (3, 6.4%) Primary bacteraemia (2, 4.3%) | P. mirabilis (47, 100%) | UK | DTC (40, 85.1%) | Carbapenem (21, 52.5%) BL/BLI (13, 32.5%) Other antibiotic therapy (6, 15%) | Y | UK | UK |
Tumbarello et al. [109] | SC retrospective cohort, 1999–2004, Italy | 186/186 | Primary bacteraemia (86, 46.2%) UTI (53, 28.4%) IIA (24, 12.9%) SSTI (20, 10.7%) Pneumonia (6, 3.2%) CVC (5, 2.7%) | E. coli (104, 55.9%) K. pneumoniae (58, 31.2%) P. mirabilis (24, 12.9%) | UK | ETC (186 100%) DTC (171, 91.9%) | BL/BLI (45, 24.2%) Fluoroquinolones (45, 24.2%) Cephalosporins (38, 20.9%) Carbapenems (29, 15.4%) Aminoglycosides (29, 15.4%) Carbapenems (61, 35.7%) BL/BLI (55, 32.2%) Aminoglycosides (30, 17.5%) Fluoroquinolones (25, 14.6%) | Y | UK | UK |
Tuon et al. [110] | SC retrospective cohort, 2006–2009, Brazil | 28/58 | UK | E. cloacae (28, 100%) | UK | DTC (25, 89.2%) | Carbapenems (15, 60%) BL/BLI (4, 16%) Non-BL/BLI (6, 24%) | N | UK | UK |
Tuon et al. [90] | SC retrospective cohort, 2006–2009, Brazil | 63/104 | UK | K. pneumoniae (63, 100%) | UK | DTC (62, 98.4%) | Carbapenems (43, 69.3%) Non-BL/BLI (17, 27.4%) BL/BLI (2, 3.1%) | N | UK | UK |
Wang et al. [95] | MC, prospective cohort, 2006–2015, USA | 68/68 | CVC (30, 44.1%) UTI (21, 30.9%) IIA (15, 22.1%) Pneumonia (10, 14.7%) SSTI (2, 2.9%) | Klebsiella sp. (42, 62%) E. coli (24, 34%) P. mirabilis (2, 3%) | Y (20, 29%) | ETC (68, 100%) | Carbapenem (51, 75%) Cephalosporins (17, 25%) | N | UK | UK |